China Health Industries Holdings Retained Earnings (Accumulated Deficit) 2016-2024 | CHHE

China Health Industries Holdings retained earnings (accumulated deficit) from 2016 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

China Health Industries Holdings Retained Earnings (Accumulated Deficit) 2016-2024 | CHHE

China Health Industries Holdings retained earnings (accumulated deficit) from 2016 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$170.6B
Vertex Pharmaceuticals (VRTX)$117.1B
Regeneron Pharmaceuticals (REGN)$111.8B
Bristol Myers Squibb (BMY)$109.9B
Gilead Sciences (GILD)$104.8B
CSL (CSLLY)$95.8B
GSK (GSK)$79.5B
Alnylam Pharmaceuticals (ALNY)$34.6B
Argenex SE (ARGX)$32.5B
BioNTech SE (BNTX)$28.5B
Biogen (BIIB)$26.9B
Moderna (MRNA)$23.5B
BeiGene (BGNE)$22.7B
Illumina (ILMN)$21.7B
Genmab (GMAB)$15.5B
BioMarin Pharmaceutical (BMRN)$12.9B
Incyte (INCY)$12.9B
Vaxcyte (PCVX)$12.4B
Exact Sciences (EXAS)$12.3B
Insmed (INSM)$12.3B
Bio-Techne Corp (TECH)$11.7B
Sarepta Therapeutics (SRPT)$11.3B
QIAGEN (QGEN)$9.9B
Bio-Rad Laboratories (BIO.B)$9.3B
Legend Biotech (LEGN)$8.7B
Roivant Sciences (ROIV)$8.3B
Ascendis Pharma (ASND)$8.2B
Repligen (RGEN)$7.8B
Revolution Medicines (RVMD)$7.7B
Halozyme Therapeutics (HALO)$7.7B